A comprehensive analysis of registered human clinical trials reveals that the global development of transcranial temporal interference stimulation, known as tTIS, is expanding rapidly but remains in an early stage of clinical maturation. The study, published in BMC Medicine, examined the landscape of registered trials to characterize registration trends, design characteristics, and reporting practices. By identifying 168 unique trials from a pool of 1,548 records, the researchers provided a detailed snapshot of how this noninvasive brain stimulation technique is being implemented across different regions and medical indications.
Despite a growing number of human studies, the global landscape of these trials had previously remained unclear. The research team aimed to address this gap by systematically examining the intervention reporting and result availability of registered tTIS trials. This characterization is crucial for understanding the current state of evidence and identifying areas where transparency and consistency in trial documentation need improvement.
The methodology involved searching nine international and regional clinical trial registries through April 30, 2026. The researchers identified human interventional trials involving tTIS or related transcranial interferential stimulation approaches. Eligible records were deduplicated and coded for various parameters, including geography, indication, intended target, enrollment size, design, stimulation parameters, device information, safety reporting, and result availability.
Geographically, the registration of tTIS trials is heavily concentrated, with China accounting for 79.8% of the included trials and the United States representing 11.3%. In terms of medical indications, psychiatric disorders were the leading group, comprising 39.8% of the trials. This distribution suggests that while the technology is being explored for various conditions, mental health applications are currently the primary focus of clinical investigation.
Several design characteristics highlight the early stage of clinical development. Most trials involved a single center, with 94.6% falling into this category, and 51.8% planned to enroll fewer than 50 participants. While randomization was reported in 69.6% of trials and masking in 74.4%, sham control was reported in 66.7%. A significant limitation in the reporting was the lack of target information, which was not reported in 75 trials, or 44.6% of the total. Among the trials that did report targets, subcortical structures predominated, aligning with the intended deep-brain engagement of tTIS.
The completeness of intervention reporting varied significantly across the included trials. Session duration was the most frequently reported stimulation parameter, appearing in 40.5% of the trials. However, device or platform information was reported in only 12.5% of the trials, which limits the ability to compare outcomes across different hardware setups. At the data cutoff, only 13 trials, or 7.7%, were classified as completed or terminated. Furthermore, results were available for only 8 trials, or 4.8%, from 10 sources. This scarcity of available results underscores the early nature of the field and the challenges in synthesizing evidence from ongoing studies.
The study concludes that while registered tTIS research is expanding across diverse indications and intended targets, clinical development remains at an early stage. The incomplete intervention reporting observed in the analysis highlights a critical need for greater transparency and consistency in trial registration. Improved documentation of stimulation parameters and device information will enhance comparability across trials, facilitate protocol replication, and support the development of a more coherent evidence base.
This analysis provides a foundational map of the current tTIS clinical landscape, identifying both the rapid growth in trial registrations and the significant gaps in reporting and result availability.
Subject of Research: Global clinical trial landscape and reporting practices for transcranial temporal interference stimulation
Article Title: Global clinical development of transcranial temporal interference stimulation: an analysis of registered human trials
Article References: Jiang, S., Liu, R., Bai, X., Li, Z., Fu, C., Wang, T., Yu, F., Ye, L., Cao, L., Wang, T., Ma, Y., Jin, J., Zhang, X., & Jiao, L. (2026). Global clinical development of transcranial temporal interference stimulation: an analysis of registered human trials. BMC Medicine. https://doi.org/10.1186/s12916-026-05363-0
Image Credits: AI Generated
DOI: 10.1186/s12916-026-05363-0
Keywords: transcranial temporal interference stimulation, clinical trials, brain stimulation, neuroscience, trial registration, psychiatric disorders, noninvasive brain stimulation, clinical development, Global, clinical, development, transcranial
News Source: Cassandra Pierce. (November 9, 2026). Analysis of 168 Trials Maps Early tTIS Clinical Development. Scienmag.



